Brian WhiteApr 4Zevtera FDA approvalFDA's approval of Basilea's 5th-generation cephalosporin antibiotic Zevtera (ceftobiprole) represents the successful culmination of the...
Andrew KeithFeb 28Basilea research reportWe published a research report today, highlighting that FY’23 has been a year of excellent execution, both financially and strategically....
Brian WhiteFeb 13Basilea full-year results - Strong executionFY'23 has been a year of excellent financial and strategic execution. FY'23 revenues of CHF157.6m were once again dominated by strong...
Brian WhiteJan 19Basilea - Cresemba LatAm milestoneGiven all of the strategic progress that Basilea has accomplished in recent months to replenish the anti-infectives pipeline, it would be...
Brian WhiteJan 15Basilea adds another antibiotic programmeContinuing its successful efforts to refill the anti-infective pipeline with new programmes, which have included the transformational...
Brian WhiteJan 5Basilea portfolio updateBasilea has provided a timely reminder of the ongoing robust performance of the existing anti-infectives portfolio, along with a...